Login / Signup

COVID-19 Evidence Accelerator: A parallel analysis to describe the use of Hydroxychloroquine with or without Azithromycin among hospitalized COVID-19 patients.

Mark StewartCarla Rodriguez-WatsonAdem AlbrayakJulius AsubontengAndrew BelliThomas BrownKelly ChoRitankar DasElizabeth EldridgeNicolle GattoAlice GelmanHanna GerlovinStuart L GoldbergEric HansenJonathan HirschYuk-Lam HoAndrew IpMonika A IzanoJason JonesAmy C JusticeReyna J KleshSeth KuranzCarson LamQingqing MaoSamson MatarasoRobertino MeraDaniel C PosnerJeremy A RassenAnna SiefkasAndrew SchragGeorgia TourassiAndrew R WecksteinFrank WolfAmar BhatSusan WincklerEllen V SigalJeff Allen
Published in: PloS one (2021)
Administration of hydroxychloroquine, azithromycin, and their combination appeared to have no effect on time to mortality in hospitalized COVID-19 patients. Continued research is needed to clarify best practices surrounding treatment of COVID-19.
Keyphrases
  • sars cov
  • coronavirus disease
  • respiratory syndrome coronavirus
  • healthcare
  • primary care
  • risk factors
  • combination therapy
  • coronary artery disease
  • cardiovascular disease